GeoVax Labs, Inc. — Q2 2011 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2011. GeoVax is a development-stage biotechnology company developing HIV vaccines; it had no products approved for sale. The unaudited statements consolidate the company and its subsidiary.
Financial performance and position
| Metric | Q2 2011 / June 30, 2011 | Comparable period / prior year-end |
|---|---|---|
| Grant revenue | $1.753 million for Q2; $2.646 million for first half | Q2 2010: $1.737 million; first half 2010: $3.076 million |
| Operating expenses | $1.965 million for Q2; $3.465 million for first half | Q2 2010: $2.678 million; first half 2010: $4.716 million |
| Net loss | $211,344 for Q2; $817,626 for first half; loss per share $0.01 and $0.05, respectively | Q2 2010: $933,089 loss; first half 2010: $1.624 million loss; loss per share $0.06 and $0.10 |
| Cash and cash equivalents | $668,055 | $1.079 million at December 31, 2010 |
| Working capital | $617,124 | $1.081 million at December 31, 2010 |
| Total assets / current liabilities | $2.134 million / $730,611 | $2.358 million / $521,608 at December 31, 2010 |
| Operating cash flow | $325,849 used in first half | $1.367 million used in first half 2010 |
| Debt | No long-term debt or committed credit lines reported |
Revenue consists of NIH grant funding recognized as related qualifying costs are incurred; it is not product sales. The filing does not provide a conventional gross margin, and reported grant revenue approximately offsets supported program costs. No operating profit was reported. Interest income was $1,451 for the first half versus $16,233 in 2010.
Changes versus comparable periods
- First-half grant revenue declined by about 14%, while total operating expenses fell about 27%; research and development expense decreased from $3.111 million to $2.224 million, and general and administrative expense from $1.605 million to $1.241 million.
- First-half net loss narrowed to $817,626 from $1.624 million. Q2 net loss narrowed to $211,344 from $933,089.
- Cash fell by $411,032 from year-end 2010, and working capital declined by about $463,000. Accounts payable and accrued expenses rose to $520,626 from $338,628.
- First-half operating cash use was lower than in 2010. Financing cash outflow was $85,183, relating to planned stock-offering costs; no stock-sale proceeds were reported in the period.
Outlook, risks, and other notable items
- Management expected existing working capital and NIH grant proceeds, excluding potential financing, to support planned operations into the first quarter of 2012. The company anticipated raising additional capital in 2011 but gave no assurance it could do so on acceptable terms.
- The NIH grant is renewable annually. The current award was $4.9 million for September 2010–August 2011; approximately $1.3 million remained at June 30. Management cited a further $3.8 million potentially available through August 2012, conditional on remaining budgeted amounts being awarded. Loss of grant funding could create a cash shortfall.
- Preventative vaccine: NIH-funded HVTN Phase 2a enrollment and inoculations were expected to finish in 2011, with full results expected in 2012. Early results remained blinded and were described as consistent with continued safety and reproducible immunogenicity.
- Therapeutic vaccine: GeoVax-sponsored Phase 1/2 trial was expected to generate safety and performance data in early 2012; expansion to Phase 2 depended on encouraging data. HVTN Phase 1 testing of the GM-CSF-adjuvanted candidate was planned for late 2011. A 70% prevention result cited for that candidate came from non-human-primate testing, not human trials.
- Research and development costs were expected to rise as clinical programs advanced. Clinical failure, regulatory delays, inability to secure future trial funding, and lack of access to capital could force the company to scale back, terminate operations, or seek a merger or acquisition.
- Unrecorded vendor and subcontractor purchase commitments were approximately $406,000, down from $942,000 at year-end 2010. Future lease payments totaled $59,300 for the remainder of 2011, followed by annual payments through 2014. Emory University is a related party; first-half expenses included $616,880 under NIH-reimbursable research agreements and $122,554 of patent-cost reimbursements.
- The filing reported no legal proceedings, no material changes to previously disclosed risk factors, and effective disclosure controls. It reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether the NIH grant is renewed or remaining grant budget is awarded, and the timing of reimbursements for grant receivables ($638,663 at June 30).
- Whether GeoVax raises additional capital and how financing terms, offering costs, or dilution affect liquidity; deferred offering costs were $515,585.
- Actual cash burn and operating runway relative to management’s Q1 2012 estimate, especially as R&D and clinical-trial spending changes.
- Clinical trial enrollment, safety and efficacy results, and the status and funding of planned studies; distinguish human data from preclinical results.
- Potential dilution from outstanding options and warrants; approximately 2.0 million potentially dilutive shares were excluded from diluted loss per share as anti-dilutive.